Tiancimycin-based antibody-drug conjugate (Scripps Research Institute)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTiancimycin-based antibody-drug conjugate (Scripps Research Institute)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsInactive tyrosine-protein kinase transmembrane receptor ROR1 modulators
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Scripps Research Institute Inc
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A